BioFocus and InterMed Discovery Announce Marketing Collaboration

21-Jul-2011 - Germany

BioFocus and InterMed Discovery GmbH (IMD) announced a marketing collaboration to offer enhanced natural product discovery to the pharmaceutical, animal health, and agrochemical industries. No financial details were disclosed.

Under the terms of the collaboration, IMD will make its natural product screening libraries available and provide follow-on services to BioFocus. BioFocus will then incorporate these as part of its own integrated drug discovery offerings. BioFocus has a track record of service deals with industry for the discovery of active ingredients in pharmaceutical, animal health and agrochemical applications.

“We believe that the combination of our natural product capabilities with the well known discovery capabilities of BioFocus will offer a powerful discovery solution at a time when there is already growing demand from the pharma, veterinary and agro industries to fill depleted pipelines,“ said Dr. Thomas Henkel, co-Managing Director of InterMed Discovery.

“We have been impressed with the scale of IMDs natural product discovery capabilities and we believe that when InterMed’s natural product libraries and services are combined with our screening services, our engine for drug discovery will be substantially enhanced and more cost-effective for our clients,” added Dr. Chris Newton, Managing Director, BioFocus.

Other news from the department business & finance

Most read news

More news from our other portals

Is artificial intelligence revolutionizing the life sciences?

Last viewed contents

Biocrea announces novel treatment opportunities for CNS diseases - Company has filed US patent on novel, brain-penetrating PDE2 and PDE10 inhibitors

Discovery of a potential new therapy for inflammatory arthritis - Researchers at the Schroeder Arthritis Institute in Toronto have made a discovery that could lead to new treatments for axial spondyloarthritis.

Discovery of a potential new therapy for inflammatory arthritis - Researchers at the Schroeder Arthritis Institute in Toronto have made a discovery that could lead to new treatments for axial spondyloarthritis.

Deadly combination: new direct trigger for cell death discovered - Understanding the basic mechanisms that lead to cell death is essential for the development of therapies for cancer and other diseases

Deadly combination: new direct trigger for cell death discovered - Understanding the basic mechanisms that lead to cell death is essential for the development of therapies for cancer and other diseases

Deuterium Depletion: A New Concept in Anticancer Drug Development

So-called junk DNA plays critical role in mammalian development - Knocking out transposon promoter leads to pup death in mice; similar promoters found in many mammals

So-called junk DNA plays critical role in mammalian development - Knocking out transposon promoter leads to pup death in mice; similar promoters found in many mammals

Leprosy strain genotyped from medieval pilgrim at UK burial site - Medieval leprosy victim in UK cemetery was likely a religious pilgrim, possibly from overseas

Biological wires carry electricity thanks to special amino acids

Bioactive novel compounds from endangered tropical plant species

Bioactive novel compounds from endangered tropical plant species

MicroRNA network study implicates rewired interactions in cancer

VAXIMM receives grant to expand pipeline of oral cancer vaccines

Merck and Pfizer receive FDA approval for kidney cancer therapy - BAVENCIO® (avelumab) plus Axitinib Combination for Patients with Advanced Renal Cell Carcinoma

New brain-computer interface allows man with ALS to ‘speak’ again - Technology developed by UC Davis Health restores interpersonal communication

New brain-computer interface allows man with ALS to ‘speak’ again - Technology developed by UC Davis Health restores interpersonal communication